{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:15:46Z","timestamp":1777486546067,"version":"3.51.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Fabry disease (FD) is an X-linked lysosomal storage disease caused by a deficiency of the enzyme alpha-galactosidase (\u03b1-Gal). Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and predominantly affects women of childbearing age. FD and SLE affect similar organs and may show overlapping features. However, the coexistence of FD with SLE is an infrequent incidence. A 12-year-old Chinese boy was diagnosed to have SLE based on the symptoms of fever, glomerular hematuria, nephrotic-range proteinuria, hypocomplementaemia, and positivity for antinuclear antibodies and anti-double-stranded deoxyribonucleic acid antibodies. Light microscopy of kidney biopsy samples revealed characteristic features of SLE (Classification IV+V). Additionally, electron microscopy of the biopsy samples demonstrated osmiophilic myelin-like bodies in the cytoplasm of glomerular podocytes.The leukocytic \u03b1-GLA activity was abnormally low. Genetic analysis showed that the patient was hemizygous for the c.G735C mutation in exon 5 of the GLA gene, which was inherited from his mother and maternal grandmother who were heterozygous and asymptomatic. Hydroxychloroquine (HCQ) administration was discontinued based on renal pathological examination results. The patient was commenced on methylprednisolone pulses and intravenous cyclophosphamide administration, followed by maintenance therapy. He was also treated with angiotensin-converting enzyme inhibitors and an angiotensin receptor blocker. This treatment regimen led to only partial improvement in the patient\u2019s condition. Enzyme replacement therapy (ERT) with agalsidase-\u03b1 (0.2 mg\/kg intravenous administration every 2 weeks) was initiated 2 months after diagnosis. The complement levels remained persistently low. Moreover, treatment with belimumab failed to improve the levels of serological markers. Following the comprehensive treatment regimen, the proteinuria levels remained stable at below 500 mg\/24 h. To the best of our knowledge, we report here the case of the youngest patient with a novel FD-related mutation coexistent with SLE. Renal biopsy plays a critical role as an indicator of FD coexisting with nephropathy. Furthermore, genetic testing could serve as a crucial assessment, particularly for male patients with SLE. This case report also addressed the controversial issue of HCQ use in patients with coexistent FD and SLE, examined the effect of ERT on proteinuria, and assessed the role of complement activation in disease progression and treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1620776","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:31:02Z","timestamp":1756704662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Fabry disease overlapping with systemic lupus erythematosus in a pediatric patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Yaqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nengjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320909156","article-title":"Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups","volume":"29","author":"Massias","year":"2020","journal-title":"Lupus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.23204","article-title":"Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus","volume":"58","author":"Brunner","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J Hum Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G>A (IVS4 + 919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01166.x","article-title":"A successful screening for Fabry disease in a Chinese dialysis patient population","volume":"76","author":"Lv","year":"2009","journal-title":"Clin Genet"},{"key":"B9","article-title":"Clinical biochemical and ultrastructural study of Fabry\u2019s disease in a child","volume":"23","author":"Loeb","year":"1968","journal-title":"Helv Paediatr Acta"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000183006","article-title":"Kidney involvement in systemic lupus erythematosus and Fabry\u2019s disease","volume":"34","author":"Rosenmann","year":"1983","journal-title":"Nephron Clin Pract"},{"key":"B11","article-title":"A case of Fabry\u2019s disease associated with lupus nephritis","volume":"34","author":"Majima","year":"1992","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"B12","article-title":"Coexistence of Fabry\u2019s disease and systemic lupus erythematosus","volume":"16","author":"Rahman","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"B13","first-page":"1","article-title":"Clinical mimicry_ Fabry:disease masquerading:as lupus_","author":"Waggoner","year":"2010","journal-title":"J Musculoskelet Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-7480.2012.07.009","article-title":"The enzymatic activity and genetic analysis of a family with one patient who have both systemic lupus erythematosus with secondary Sj(o)gren\u2019s syndrome and Fabry disease","volume":"16","author":"Ya","year":"2012","journal-title":"Chin J Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313497116","article-title":"Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry\u2019s disease","volume":"22","author":"Nandagudi","year":"2013","journal-title":"Lupus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151357","article-title":"Heart involvement in a woman treated with hydroxychloroquine for systemic lupus erythematosus revealing fabry disease","volume":"43","author":"Chatre","year":"2016","journal-title":"J Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320928396","article-title":"Severe lupus nephritis: an unexpected association with Fabry disease","volume":"29","author":"Conigliaro","year":"2020","journal-title":"Lupus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320983458","article-title":"Protenuria in SLE: Is it always lupus","volume":"30","author":"Celia","year":"2021","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e14419","DOI":"10.1111\/nep.14419","article-title":"Concurrent Fabry disease and IgA nephropathy in a patient with Crohn\u2019s disease: A case report","volume":"30","author":"Choi","year":"2025","journal-title":"Nephrol (Carlton)"},{"key":"B20","article-title":"Coexistence of fabry disease and membranous nephropathy: A case report","volume":"18","author":"Jin","year":"2024","journal-title":"Iran J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e17566","DOI":"10.1097\/MD.0000000000017566","article-title":"Coexistence of Fabry disease with IgM nephropathy: A case report","volume":"98","author":"Wu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1219690842","DOI":"10.1177\/0300060519891290","article-title":"IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report","volume":"48","author":"Hao","year":"2020","journal-title":"J Int Med Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0513-2","article-title":"High incidence of autoantibodies in Fabry disease patients","volume":"30","author":"Martinez","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5606\/ArchRheumatol.2020.7135","article-title":"Screening for fabry disease in patients with juvenile systemic lupus erythematosus","volume":"35","author":"Kiykim","year":"2020","journal-title":"Arch Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2021.106584","article-title":"Role of sphingosine-1-phosphate mediated signalling in systemic lupus erythematosus","volume":"156","author":"Tian","year":"2021","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B26","doi-asserted-by":"publisher","first-page":"104170","DOI":"10.1016\/j.phrs.2019.02.009","article-title":"Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases","volume":"154","author":"Stepanovska","year":"2020","journal-title":"Pharmacol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316686707","article-title":"Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study","volume":"26","author":"Checa","year":"2017","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e53521","DOI":"10.1371\/journal.pone.0053521","article-title":"Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis","volume":"8","author":"Snider","year":"2013","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030210","article-title":"Targeted cellular treatment of systemic lupus erythematosus","volume":"14","author":"Athanassiou","year":"2025","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kint.2018.02.003","article-title":"Hydroxychloroquine-induced mimic of renal Fabry disease","volume":"94","author":"Sperati","year":"2018","journal-title":"Kidney Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3899\/jrheum.170689","article-title":"Chloroquine toxicity misdiagnosed as fabry disease associated with systemic lupus erythematosus and hashimoto thyroiditis","volume":"44","author":"Navratil","year":"2017","journal-title":"J Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228876","article-title":"Hydroxychloroquine-induced podocytopathy mimicking Fabry disease","volume":"12","author":"Serre","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101079","article-title":"Does administration of hydroxychloroquine\/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice","volume":"39","author":"Tsukimura","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13023-024-03441-1","article-title":"Effectiveness and safety of enzyme replacement therapy in the treatment of Fabry disease: a Chinese monocentric real-world study","volume":"19","author":"Liu","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.33594\/000000077","article-title":"Enzyme replacement therapy clears gb3 deposits from a podocyte cell culture model of fabry disease but fails to restore altered cellular signaling","volume":"52","author":"Braun","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010206","article-title":"Fabry disease therapy: state-of-the-art and current challenges","volume":"22","author":"Azevedo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e20240035","DOI":"10.1590\/2175-8239-JBN-2024-0035en","article-title":"The role of podocyte injury in the pathogenesis of Fabry disease nephropathy","volume":"46","author":"Monte","year":"2024","journal-title":"J Bras Nefrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw094","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-024-03389-4","article-title":"Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study","volume":"26","author":"Su","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead707","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study","volume":"64","author":"Lin","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy","volume":"54","author":"Heo","year":"2017","journal-title":"J Med Genet"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1307558","article-title":"Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy","volume":"15","author":"Laffer","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:31:06Z","timestamp":1756704666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2025.1620776"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620776","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1620776"}}